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A harmine-derived beta-carboline, CM16, inhibits cancer cells
growth through its effects on protein synthesis, as described in “A
harmine-derived beta-carboline displays anti-cancer effects
in vitro by targeting protein synthesis” (Carvalho et al., 2017)[1].
This data article provides accompanying data on CM16 cytostatic
evaluation in cancer cells as well as data related to its effects on
transcription and translation. After confirming the cytostatic effect
of CM16, we investigated its ability to arrest the cell cycle in the
glioma Hs683 and SKMEL-28 melanoma cell lines but no mod-
ification was evidenced. According to the global protein synthesis
inhibition induced by CM16 [1], transcription phase, a step prior to
mRNA translation, evaluated by labelled nucleotide incorporation
assay was not shown to be affected under CM16 treatment in the
two cell lines. By contrast, mRNA translation and particularly the
initiation step were shown to be targeted by CM16 in [1]. Tois an open access article under the CC BY license
/j.ejphar.2017.03.034
e et Toxicologie Expérimentale – Faculté de Pharmacie – Université Libre de









A. Carvalho et al. / Data in Brief 12 (2017) 546–551 547further decipher those effects, we established herein a list of main
actors in the protein synthesis process according to literature
survey for comparative analysis of cell lines displaying different
sensitivity levels to CM16. Finally, one of these proteins, PERK, a
kinase regulating eIF2-α phosphorylation and thereby activity, was
evaluated under treatment with CM16 in a cell-free system.
& 2017 Published by Elsevier Inc. This is an open access article
under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Specifications tableubject area Biology
ore specific
subject areaProtein synthesis inhibition of cancer cells in vitro
Mechanism of action of potential anticancer drugype of data Graphs and table
ow data was
acquiredFlow cytometer, microplate reader, search on databasesata format Analyzed graphs and raw data retrieval (table)
xperimental
factorsAs in the description of the data and materials and methodsxperimental
featuresAs in the description of the data and materials and methodsata source
locationLab. de Cancérologie et Toxicologie Experimentale, Université Libre de Bruxelles,
Brussels, Belgium.
Life Technologies, Madison, USAata accessibility Data is with this articleD2. Value of the data This data offers an extended comprehension of CM16 mechanism of action as a protein synthesis
inhibitor in cancer cells.
 Assays performed to evaluate transcription and translation initiation provide valuable data and
may be used as tools in other cell-based investigations of potential protein synthesis inhibitors.
 The data presented shows that different methods add to and enrich the investigation of the
mechanism of action of proteins synthesis inhibitors in cancer cells. Therefore, these approaches
might be useful in similar studies.3. Data
Firstly, data on CM16-induced cytostatic effects is presented. As shown in [1] CM16 displays
cytostatic effects at its IC50 in glioma Hs683, melanoma SKMEL-28 and breast adenocarcinoma MDA-
MB-231 cells. Thus, CM16 effect on the cell cycle of both glioma Hs683 (Fig. 1A) cells and SKMEL-28
(Fig. 1B) are presented. After data showing CM16 inhibiting translation [1], further investigation on































































Fig. 2. Effects of CM16 on newly synthesized mRNA in A: Hs683 and B: SKMEL-28 cell lines. Results are expressed as the mean
neosynthesized RNA amounts normalized to the control (100%) 7 S.E.M. of six replicates. No significant effects were observed












































Fig. 1. Cell cycle effects of CM16 on A: Hs683 at 0.1 mM; and B: SKMEL-28 at 0.5 mM. Data are expressed as the mean percentage
of cells in each phase of the cell cycle of four replicates. As proliferation inhibition were observed on the three cancer models
under study at their GI50 and the lack of evidence of any effects of CM16 on the cell cycle of Hs683 and SKMEL-28, we did not
perform the cell cycle analysis on MDAMB-231.
A. Carvalho et al. / Data in Brief 12 (2017) 546–551548data here shown (Fig. 2A-B). CM16 effects on PERK activity, is shown in Fig. 3. The data on Table 1
refers to the genes related to translation that were analyzed for their transcriptomic expression in the
cell lines most and least sensitive to CM16 effects, according to the NCI 60-cell-line growth inhibitory
evaluation [1].
Fig. 3. PERK kinase activity in vitro in the presence or absence of CM16.
A. Carvalho et al. / Data in Brief 12 (2017) 546–551 5494. Experimental design, materials and methods
4.1. Cell lines and compound
The human cancer cell lines, oligodendroglioma Hs683 (ATCC code HTB-138) and melanoma
SKMEL-28 (ATCC code HTB-72) were herein used. Cells were cultivated at 37 °C with 5% CO2 in RPMI
culture medium supplemented with 10% FBS, 200U penicillin–streptomycin, 0.1 mg/ml gentamicin
and 4 mM L-glutamine. CM16 was synthetized as previously described [2] and the experiments were
designed with the cell lines described above treated with different concentrations of CM16, based on
its IC50.
4.2. Analysis of CM16 effects on cell cycle
Cell cycle analysis was performed with flow cytometry through the measurements of DNA content
with propidium iodide. Hs683 and SKMEL-28 were seeded in cell culture flasks and left untreated or
treated with CM16 at its respective IC50 in each cell line for 24 h, 48 h and 72 h. The samples were
then centrifuged (10 min, 1500 rcf, 4 °C), resuspended in PBS and pellets were resuspended in cold
ethanol 70% for fixation. Staining with 0.08 mg/ml propidium iodide solution (0.08 mg/ml PI; 0.2 mg/
ml RNAse in PBS) followed after a PBS wash. The samples were incubated at 37 °C for 30 min and
stored at 4 °C for a few hours. Analysis was performed with the Cell Lab Quanta (Beckman Coulter,
Analis, Suarlée, Belgium). The experiment was performed once in quadruplicate.
4.3. Analysis of CM16 effects on transcription
Neosynthesized RNA was evaluated through incorporation of a nucleoside analog, 5-ethynyl-uri-
dine, using the Click iT-RNA HCS (Invitrogen, Life Technologies, Merelbeke, Belgium). The alkyne-
containing nucleosides react with a fluorescent dye containing the azide moiety after their incor-
poration into cellular RNA. Briefly, Hs683 or SKMEL-28 cells were seeded and after attachment they
were either left untreated (negative control) or treated with CM16 or the positive control actinomycin
(Life Technologies, Paisley, UK). After the treatment with the analog 5-ethynyl uridine (4 mM) for two
h, the cells were fixed, stained (Alexa Fluor 488 and 594) and fluorescence readings (ex/em: 495/
520 nm) were carried out in microplate reader (SynergyMX Biotek, Winooski, USA: ex/em: 350/
460 nm). Normalization according to cell number was carried out as described in the user manual
with Hoescht counterstaining. The experiment was performed once in sextuplicate.
4.4. PERK inhibition
PERK activity was evaluated by the Life Technologies screening service (Lantha Screen, Madison,
USA). The in vitro assay used is based on FRET between a terbium-labeled antibody and the phos-
phorylated product of the active kinase: TR-FRET increases proportionally to their binding and
thereby to the quantity of the phosphorylated product. CM16 compound at different concentrations
Table 1







Eukaryotic translation initiation factor 2 subunit 1 P05198 EIF2S1 1965
Eukaryotic translation initiation factor 2 subunit 2 P20042 EIF2S2 8894
Eukaryotic translation initiation factor 2 subunit 3 P41091 EIF2S3 1968
Translation initiation factor eIF-2B subunit alpha Q14232 EIF2B1 1967
Translation initiation factor eIF-2B subunit beta P49770 EIF2B2 8892
Translation initiation factor eIF-2B subunit gamma Q9NR50 EIF2B3 8891
Translation initiation factor eIF-2B subunit delta Q9UI10 EIF2B4 8890
Translation initiation factor eIF-2B subunit epsilon Q13144 EIF2B5 8893
Eukaryotic translation initiation factor 4E P06730 EIF4E 1977
Eukaryotic translation initiation factor 4E-binding protein 1 Q13541 EIF4EBP1 1978
Eukaryotic translation initiation factor 4 gamma 1 Q04637 EIF4G1 1981
Eukaryotic translation initiation factor 4 gamma 2 P78344 EIF4G2 1982
Eukaryotic translation initiation factor 4 gamma 3 O43432 EIF4G3 8672
MAP kinase-interacting serine/threonine-protein kinase 1 Q9BUB5 MKNK1 8569
MAP kinase-interacting serine/threonine-protein kinase 2 Q9HBH9 MKNK2 2872
Eukaryotic initiation factor 4A-I P60842 EIF4A1 1973
Eukaryotic initiation factor 4A-II Q14240 EIF4A2 1974
Eukaryotic initiation factor 4A-III P38919 EIF4A3 9775
Programmed cell death protein 4 Q53EL6 PDCD4 27250
Eukaryotic translation initiation factor 5A-1 P63241 EIF5A 1984
Eukaryotic translation initiation factor 5A-2 Q9GZV4 EIF5A2 56648
Eukaryotic translation initiation factor 5B O60841 EIF5B 9669
Eukaryotic translation initiation factor 6 P56537 EIF6 3692
Eukaryotic translation initiation factor 1 P41567 EIF1 10209
Eukaryotic translation initiation factor 1A, X-chromosomal P47813 EIF1AX 1964
Eukaryotic translation initiation factor 1A, Y-chromosomal O14602 EIF1AY 9086
Probable RNA-binding protein EIF1AD Q8N9N8 EIF1AD 84285
Eukaryotic translation initiation factor 3 subunit A Q14152 EIF3A 8661
Eukaryotic translation initiation factor 3 subunit B P55884 EIF3B 8662
Eukaryotic translation initiation factor 3 subunit H O15372 EIF3H 8667
Eukaryotic translation initiation factor 3 subunit I Q13347 EIF3I 8668
Eukaryotic translation initiation factor 3 subunit M Q7L2H7 EIF3M 10480
Eukaryotic translation initiation factor 3 subunit E P60228 EIF3E 3646
Eukaryotic translation initiation factor 3 subunit F O00303 EIF3F 8665
Eukaryotic translation initiation factor 2-alpha kinase 3 Q9NZJ5 EIF2AK3 9451
Eukaryotic translation initiation factor 2-alpha kinase 4 Q9P2K8 EIF2AK4 440275
Interferon-induced, double-stranded RNA-activated protein kinase P19525 EIF2AK2 5610
Eukaryotic translation initiation factor 2-alpha kinase 1 Q9BQI3 EIF2AK1 27102
Elongation factor 1-alpha 1 P68104 EEF1A1 1915
Elongation factor 2 P13639 EEF2 1938
Serine/threonine-protein kinase mTOR P42345 MTOR 2475
RAC-alpha serine/threonine-protein kinase P31749 AKT1 207
RAC-beta serine/threonine-protein kinase P31751 AKT2 208
RAC-gamma serine/threonine-protein kinase Q9Y243 AKT3 10000
Ribosomal protein S6 kinase beta-1 P23443 RPS6KB1 6198
Ribosomal protein S6 kinase beta-2 Q9UBS0 RPS6KB2 6199
Myc proto-oncogene protein P01106 MYC 4609
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha
isoform
P42336 PIK3CA 5290
Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-spe-
cificity protein phosphatase PTEN
P60484 PTEN 5728
Hamartin Q92574 TSC1 7248
Tuberin P49815 TSC2 7249
Cellular tumor antigen p53 P04637 TP53 7157
Retinoblastoma-associated protein P06400 RB1 5925
3-phosphoinositide-dependent protein kinase 1 O15530 PDPK1 5170
Mitogen-activated protein kinase 1 P28482 MAPK1 5594
Vascular endothelial growth factor A P15692 VEGFA 7742
78 kDa glucose-regulated protein P11021 HSPA5 3309
Data retrieved from: www.proteinatlas.com; www.uniprot.org; www.genenames.org and http://www.ncbi.nlm.nih.gov/gene in
September 2015.
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A. Carvalho et al. / Data in Brief 12 (2017) 546–551 551or the control solutions were mixed with the kinase/substrate/ATP mixture into the wells. After
60 min of reaction at room temperature, the detection mix was added and left to equilibrate for an h
prior to fluorescence reading.Acknowledgements
The Ph.D of A.C. is financially supported by the Coordenação de Aperfeiçoamento de Pessoal de
Nivel Superior (Grant 0674-13/3;CAPES; Brazil). C.M. acknowledges the grant from the Télévie (Grant
7.4529.13; FRS-FNRS; Belgium). R.K. is a director of research with the Fonds National de la Recherche
Scientifique (FRS-FNRS; Belgium) that supported the present project (#3.4525.11: Anti-cancéreux
dérivés de l’harmine from 2010 to 2014). Part of this study is also supported by the grant by the
Belgian Brain Tumor Support (BBTS; Belgium). We thank Mohsin Mssassi for his help during his stay
in the Laboratoire of Cancérologie et Toxicologie Expérimentale (ULB, Belgium). JP acknowledges
grants from the Canadian Institutes of Health Research (MOP-106530 and MOP-115126). A.K.
acknowledges the National Cancer Institute (CA186046-01A1) and Welch Foundation (AI-0045).Transparency document. Supporting information
Transparency data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2017.05.006.References
[1] A. Carvalho, J. Chu, C. Meinguet, R. Kiss, G. Vandenbussche, B. Masereel, et al., A harmine-derived beta-carboline displays
anti-cancer effects in vitro by targeting protein synthesis, Eur. J. Pharmacol. (2017), http://dx.doi.org/10.1016/j.
ejphar.2017.03.034.
[2] C. Meinguet, C. Bruyère, R. Frédérick, V. Mathieu, C. Vancraeynest, L. Pochet, et al., 3D-QSAR, design, synthesis and char-
acterization of trisubstituted harmine derivatives with in vitro antiproliferative properties, Eur. J. Med. Chem. 94 (2015)
45–55. http://dx.doi.org/10.1016/j.ejmech.2015.02.044.
